Diabetes, Vol 36, Issue 3 374-381, Copyright © 1987 by American Diabetes Association

ARTICLES

Studies on macromolecular components of human glomerular basement membrane and alterations in diabetes. Decreased levels of heparan sulfate proteoglycan and laminin

H Shimomura and RG Spiro

Treatment of human glomerular basement membrane (GBM) with 4 M guanidine HCl resulted in a preferential extraction of noncollagenous components including laminin, fibronectin, entactin, and heparan sulfate proteoglycan, whereas effective solubilization of type IV collagen required exposure to denaturing solvents in the presence of reducing agents. The guanidine HCl-solubilized constituents were identified by immunochemical procedures after resolution by polyacrylamide gel electrophoresis, CL-6B filtration, and DEAE-cellulose chromatography. Two immunologically related heparan sulfate proteoglycans (Mr approximately 350,000 and 210,000) were observed by electrophoresis, with the higher-molecular-weight form being predominant. An examination of the two proteoglycans after heparitinase digestion or chemical deglycosylation indicated that heparan sulfate chains and other carbohydrate units are attached to core proteins with Mr approximately 140,000 and 110,000, respectively. Radioimmunoassays indicated that human diabetic GBM contained significantly lower (P less than .005) amounts of heparan sulfate proteoglycan and laminin with average values that were 30 and 60%, respectively, of nondiabetic controls; the fibronectin content of the diabetic GBM, however, was not significantly different from the normal. These findings, together with previous studies showing increases in GBM collagen, indicate that an alteration in the macromolecular architecture of this basement membrane occurs in diabetes that may be responsible for the filtration defect and the ultimate glomerular occlusion.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. Han, A. E. Woytowich, A. K. Mandal, and L. M. Hiebert Heparanase Upregulation in High Glucose-Treated Endothelial Cells Is Prevented by Insulin and Heparin Experimental Biology and Medicine, July 1, 2007; 232(7): 927 - 934. [Abstract] [Full Text] [PDF]

				A. S. Morss and E. R. Edelman Glucose Modulates Basement Membrane Fibroblast Growth Factor-2 via Alterations in Endothelial Cell Permeability J. Biol. Chem., May 11, 2007; 282(19): 14635 - 14644. [Abstract] [Full Text] [PDF]

				K. Yozai, K. Shikata, M. Sasaki, A. Tone, S. Ohga, H. Usui, S. Okada, J. Wada, R. Nagase, D. Ogawa, et al. Methotrexate Prevents Renal Injury in Experimental Diabetic Rats via Anti-Inflammatory Actions J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3326 - 3338. [Abstract] [Full Text] [PDF]

				J. B. Maxhimer, M. Somenek, G. Rao, C. E. Pesce, D. Baldwin Jr., P. Gattuso, M. M. Schwartz, E. J. Lewis, R. A. Prinz, and X. Xu Heparanase-1 Gene Expression and Regulation by High Glucose in Renal Epithelial Cells: A Potential Role in the Pathogenesis of Proteinuria in Diabetic Patients Diabetes, July 1, 2005; 54(7): 2172 - 2178. [Abstract] [Full Text] [PDF]

				C. A. Vogl-Willis and I. J. Edwards High Glucose-Induced Alterations in Subendothelial Matrix Perlecan Leads to Increased Monocyte Binding Arterioscler. Thromb. Vasc. Biol., May 1, 2004; 24(5): 858 - 863. [Abstract] [Full Text]

				P.-T. Brinkkoetter, S. Holtgrefe, F. J. van der Woude, and B. A. Yard Angiotensin II Type 1-Receptor Mediated Changes in Heparan Sulfate Proteoglycans in Human SV40 Transformed Podocytes J. Am. Soc. Nephrol., January 1, 2004; 15(1): 33 - 40. [Abstract] [Full Text] [PDF]

				R. M. Mason and N. A. Wahab Extracellular Matrix Metabolism in Diabetic Nephropathy J. Am. Soc. Nephrol., May 1, 2003; 14(5): 1358 - 1373. [Abstract] [Full Text] [PDF]

				A. Jager, P. J. Kostense, G. Nijpels, J. M. Dekker, R. J. Heine, L. M. Bouter, A. J. M. Donker, and C. D. A. Stehouwer Serum Homocysteine Levels Are Associated With the Development of (Micro)albuminuria : The Hoorn Study Arterioscler. Thromb. Vasc. Biol., January 1, 2001; 21(1): 74 - 81. [Abstract] [Full Text] [PDF]

				G. GAMBARO and F. J. VAN DER WOUDE Glycosaminoglycans: Use in Treatment of DiabeticNephropathy J. Am. Soc. Nephrol., February 1, 2000; 11(2): 359 - 368. [Full Text] [PDF]

				C. J. I. Raats, M. A. H. Bakker, W. Hoch, W. P. M. Tamboer, A. J. A. Groffen, L. P. W. J. van den Heuvel, J. H. M. Berden, and J. van den Born Differential Expression of Agrin in Renal Basement Membranes As Revealed by Domain-specific Antibodies J. Biol. Chem., July 10, 1998; 273(28): 17832 - 17838. [Abstract] [Full Text] [PDF]

				M. J. Burne, Y. Adal, N. Cohen, S. Panagiotopoulos, G. Jerums, and W. D. Comper Anomalous decrease in dextran sulfate clearance in the diabetic rat kidney Am J Physiol Renal Physiol, April 1, 1998; 274(4): F700 - F708. [Abstract] [Full Text] [PDF]

				J. Kuusisto, L. Mykkanen, K. Pyorala, and M. Laakso Hyperinsulinemic Microalbuminuria : A New Risk Indicator for Coronary Heart Disease Circulation, February 1, 1995; 91(3): 831 - 837. [Abstract] [Full Text]